These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 12116753)
21. [Treatment of the overactive bladder with detrusitol]. Golomb J Harefuah; 2000 Dec; 139(11-12):467-70. PubMed ID: 11341197 [No Abstract] [Full Text] [Related]
22. PHARMAC responds on tolterodine for overactive bladder. Moodie P N Z Med J; 2005 Feb; 119(1229):U1871. PubMed ID: 16498471 [No Abstract] [Full Text] [Related]
23. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. Athanasopoulos AA; Perimenis PS BJU Int; 2005 May; 95(7):1117-8. PubMed ID: 15839945 [No Abstract] [Full Text] [Related]
25. Tolterodine for overactive bladder. Med Lett Drugs Ther; 1998 Oct; 40(1038):101-2. PubMed ID: 9813595 [No Abstract] [Full Text] [Related]
26. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults. Roberts RG; Garely AD; Bavendam T Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389 [TBL] [Abstract][Full Text] [Related]
27. Should we switch over to tolterodine in every child with non-neurogenic daytime urinary incontinence in whom oxybutynin failed? Yucel S; Akkaya E; Guntekin E; Kukul E; Danisman A; Akman S; Baykara M Urology; 2005 Feb; 65(2):369-73. PubMed ID: 15708055 [TBL] [Abstract][Full Text] [Related]
32. Urinary incontinence in women. Wilkinson E Nurs Times; 2006 Nov 28-Dec 4; 102(48):23-4. PubMed ID: 17193773 [TBL] [Abstract][Full Text] [Related]
33. Patients with overactive bladders deserve better. Brenner B; Rice M N Z Med J; 2006 Feb; 119(1229):U1846. PubMed ID: 16498474 [TBL] [Abstract][Full Text] [Related]
35. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates. Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386 [TBL] [Abstract][Full Text] [Related]
36. Re: safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. Schaefer W J Urol; 2006 Nov; 176(5):2311-2; author reply 2312-3. PubMed ID: 17070326 [No Abstract] [Full Text] [Related]
37. Clinical advances in incontinence management. A sampling of products now available to manage urinary incontinence. Adv Skin Wound Care; 2000; 13(6):290-2. PubMed ID: 12669676 [No Abstract] [Full Text] [Related]
38. Does urodynamic verification of overactive bladder determine treatment success? Results from a randomized placebo-controlled study. Malone-Lee JG; Al-Buheissi S BJU Int; 2009 Apr; 103(7):931-7. PubMed ID: 19281469 [TBL] [Abstract][Full Text] [Related]
39. Use of the short form of King's Health Questionnaire to measure quality of life in patients with an overactive bladder. Homma Y; Uemura S BJU Int; 2004 May; 93(7):1009-13. PubMed ID: 15142153 [TBL] [Abstract][Full Text] [Related]